Free Trial

Nyxoah Q3 2023 Earnings Report

Nyxoah logo
$6.99 +0.49 (+7.54%)
As of 04:00 PM Eastern

Nyxoah EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
$1.06 million
Expected Revenue
$1.50 million
Beat/Miss
Missed by -$440.00 thousand
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Nyxoah Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Kepler Capital Remains a Buy on Nyxoah (NYXH)
HC Wainwright Has Positive Outlook for Nyxoah Q1 Earnings
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

View Nyxoah Profile

More Earnings Resources from MarketBeat